1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护

doi:10.19803/j.1672-8629.2022.07.19

中国药物警戒 ›› 2022, Vol. 19 ›› Issue (7): 782-785.
DOI: 10.19803/j.1672-8629.2022.07.19

1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护

孙雪林¹, 张攀², 胡欣^1,*

¹北京医院药学部,国家老年医学研究中心,中国医学科学院老年医学研究院,药物临床风险与个体化应用评价北京市重点实验室,北京 100730;
²北京医院消化科,北京 100730

收稿日期:2021-04-21 出版日期:2022-07-15 发布日期:2022-07-12
通讯作者: ^*胡欣,男,博士,主任药师,医院药学。E-mail：huxinbjyy@126.com
作者简介:孙雪林,女,博士,副主任药师,临床药学。
基金资助:
国家重点研发计划（2020YFC2009000,2009001）

Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab

SUN Xuelin¹, ZHANG Pan², HU Xin^1,*

¹Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Beijing 100730, China;
²Department of Gastroenterology, Beijing Hospital, Beijing 100730, China

Received:2021-04-21 Online:2022-07-15 Published:2022-07-12

摘要/Abstract

摘要： 目的探讨临床药师在维得利珠单抗（vedolizumab, Ved）治疗重症溃疡性结肠炎(ulcerative colitis, UC)的作用和药学监护模式。方法临床药师参与1例重症UC的药物治疗,该患者对5-氨基水杨酸（5-aminosalicylic acid,5-ASA）和糖皮质激素治疗症状改善不明显,结合患者病情,药师推荐使用Ved进行治疗,并对患者进行全程药学监护。结果患者用药后UC症状逐步好转,使用Ved治疗期间未发生严重的不良反应,Ved对美沙拉嗪和糖皮质激素治疗症状改善不明显的重症UC患者有效。结论临床药师参与治疗方案的制定,提供药学服务有助于提高重症UC的治疗效果,保障患者安全用药,提高UC患者的预后和生活质量。

关键词: 溃疡性结肠炎, 维得利珠单抗, 药学监护, 临床药师

Abstract: Objective To explore the role of clinical pharmacists in the treatment of severe ulcerative colitis (UC) with vedolizumab and pharmaceutical care model. Methods The clinical pharmacist participated in the drug treatment of a case of severe UC, and the patient's symptoms were not significantly improved by 5-aminosalicylic acid and glucocorticoid treatment. Considering the patient's condition, the pharmacist recommended vedolizumab for treatment, and the patient was given full pharmaceutical monitoring. Results Patients with UC symptoms gradually improved after medication, and no serious adverse reactions occurred during the treatment with vedolizumab. Vedolizumab was effective in UC patients whose symptoms were not significantly improved after treatment with mesalazine and glucocorticoid. Conclusion The participation of clinical pharmacists in the formulation of treatment plans and the provision of pharmaceutical care are helpful to improve of the drug efficacy in severe UC, ensuring the safety of drugs, and improving the prognosis and quality of life of patients with UC.

Key words: ulcerative colitis, vedolizumab, pharmaceutical care, clinical pharmacists

中图分类号:

R979.1

孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.

SUN Xuelin, ZHANG Pan, HU Xin. Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 782-785.

参考文献

[1] SATSANGI J, SILVERBERG MS, VERMEIRE S, et al.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications[J]. Gut, 2006, 55(6): 749-753.
[2] LIU AL, LYU H, QIAN JM.Management of acute severe ulcerative colitis[J]. Chinese Journal of Gastroenterology(胃肠病学), 2019, 24(6): 321-325.
[3] WANG LB, TANG SQ.Progress in the treatment of ulcerative colitis with biological agents[J]. Chinese Journal of Postgraduates of Medicine(中国医师进修杂志), 2020, 43(12): 1141-1144.
[4] FEUERSTEIN JD, ISAACS KL, SCHNEIDER Y, et al.AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis[J]. Gastroenterology, 2020, 158(5): 1450-1461.
[5] DA SILVA BC, LYRA AC, ROCHA R, et al.Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis[J]. World J Gastroenterol, 2014, 20(28): 9458-9467.
[6] Inflammatory bowel disease group, Chinese society of gastroen-terology, Chinese medical association. Chinese consensus diagnosis and treatment of inflammatory bowel disease(Beijing, 2018)[J]. Chinese Journal of Digestion(中华消化杂志), 2018, 38(5): 292-311.
[7] DASSOPOULOS T, COHEN RD, SCHERL EJ, et al.Ulcerative colitis care pathway[J]. Gastroenterology, 2015, 149(1): 238-245.
[8] RUBIN DT, ANANTHAKRISHNAN AN, SIEGEL CA, et al.ACG clinical guideline: ulcerative colitis in adults[J]. Am J Gastroenterol, 2019, 114(3): 384-413.
[9] UNGARO R, MEHANDRU S, ALLEN PB, et al.Ulcerative colitis[J]. Lancet, 2017, 389(10080): 1756-1770.
[10] TIMMER A, PATTON PH, CHANDE N, et al. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis[J]. Cochrane Database Syst Rev, 2016, 2016(5): CD000478.
[11] PUGLIESE D, FELICE C, PAPA A, et al.Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future[J]. Expert Rev Clin Immunol, 2017, 13(3): 223-233.
[12] ARGOLLO M, KOTZE PG, KAKKADASAM P, et al.Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?[J]. Nat Rev Gastroenterol Hepatol, 2020, 17(11): 702-710.
[13] LI K, TONG YL, YU XF.Nutritional support for inflammatory bowel disease[J]. International Journal of Digestive Diseases(国际消化病杂志), 2015, 35(3): 171-173, 221.
[14] GLICK LR, CIFU AS, FELD L.Ulcerative colitis in adults[J]. JAMA, 2020, 324(12): 1205-1206.
[15] LICHTENSTEIN L, RON Y, KIVITY S, et al.Infliximab-related infusion reactions: systematic review[J]. J Crohns Colitis, 2015, 9(9): 806-815.
[16] LUTHRA P, PEYRIN-BIROULET L, FORD AC.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease[J]. Aliment Pharmacol Ther, 2015, 41(12): 1227-1236.
[17] FEAGAN BG, RUTGEERTS P, SANDS BE, et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis[J]. N Engl J Med, 2013, 369(8): 699-710.
[18] NOVAK G, HINDRYCKX P, KHANNA R, et al.The safety of vedolizumab for the treatment of ulcerative colitis[J]. Expert Opin Drug Saf, 2017, 16(4): 501-507.
[19] COLOMBEL JF, SANDS BE, RUTGEERTS P, et al.The safety of vedolizumab for ulcerative colitis and Crohn's disease[J]. Gut, 2017, 66(5): 839-851.
[20] LOFTUS EV JR, COLOMBEL JF, FEAGAN BG, et al.Long-term efficacy of vedolizumab for ulcerative colitis[J]. J Crohns Colitis, 2017, 11(4): 400-411.
[21] SANDS BE, PEYRIN-BIROULET L, LOFTUS EV JR, et al.Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis[J]. N Engl J Med, 2019, 381(13):1215-1226.
[22] TAKATSU N, HISABE T, HIGASHI D, et al.Vedolizumab in the treatment of ulcerative colitis: an evidence-based review of safety, efficacy, and place of therapy[J]. Core Evid, 2020, 15: 7-20.
[23] MCLEAN LP, CROSS RK.Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis published correction appears in Expert Opin Drug Metab Toxicol[J]. Expert Opin Drug Metab Toxicol, 2016, 12(7): 833-842.

1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护

Pharmaceutical care of a case of severe ulcerative colitis treated with vedolizumab

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	张夏兰, 袁静, 吴斌, 秦媛媛. 甲磺酸阿帕替尼在恶性肿瘤患者的用药特征分析[J]. 中国药物警戒, 2023, 20(8): 927-932.
[3]	王然, 李轶凡, 刘小艳, 冯欣. 1例妊娠期药物暴露风险的药学监护[J]. 中国药物警戒, 2023, 20(8): 933-934.
[4]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[5]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[6]	杨岩, 周德喜, 吴欣俐, 薛淑雅, 丁海华, 张泉, 张云玲. 84例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2023, 20(3): 334-338.
[7]	姚鑫, 葛秋格, 李亚敏, 王一帆, 李媛媛, 刘志强. 2018~2022年某院新型抗肿瘤药物消化系统不良反应分析[J]. 中国药物警戒, 2023, 20(11): 1273-1278.
[8]	郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.
[9]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[10]	王燕婷, 张媛媛, 陈怡然, 孙捷, 朱宇, 杨荔艳, 吴知桂, 申丽君, 程敏, 李国辉. 1例恶性肿瘤患者抗感染与抗肿瘤治疗的平衡抉择及药学监护[J]. 中国药物警戒, 2023, 20(10): 1168-1172.
[11]	王祺茹, 左丽, 杜琼, 叶玲, 阮聪, 翟青, 徐蕊. 1例奥拉帕利致Ⅳ度骨髓抑制患者的药学监护[J]. 中国药物警戒, 2023, 20(10): 1176-1180.
[12]	卫红涛, 沈素, 李丹丹, 廖音. 705例神经内科问题医嘱的帕累托图分析[J]. 中国药物警戒, 2022, 19(8): 900-903.
[13]	原小陇, 万齐华, 陶东红, 祁浩, 王爱霞. 1例甲氨蝶呤片严重中毒患者的药学监护[J]. 中国药物警戒, 2022, 19(8): 924-928.
[14]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[15]	李雁铭, 赵志刚. 基于循证的伊布替尼不良反应及药学监护[J]. 中国药物警戒, 2022, 19(7): 807-811.